404 related articles for article (PubMed ID: 19940606)
1. Therapeutic implications of diabetes in cardiovascular disease.
Cherian B; Meka N; Katragadda S; Arora R
Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
[TBL] [Abstract][Full Text] [Related]
2. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm.
Deedwania PC; Fonseca VA
Am J Med; 2005 Sep; 118(9):939-47. PubMed ID: 16164876
[TBL] [Abstract][Full Text] [Related]
3. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
Roman G; Hancu N
Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
[TBL] [Abstract][Full Text] [Related]
4. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
5. Prevention of type 2 diabetes in the prediabetic population.
Maji D; Roy RU; Das S
J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
[TBL] [Abstract][Full Text] [Related]
6. Reflecting on type 2 diabetes prevention: more questions than answers!
Rosenstock J
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
8. Drug therapy in prediabetes.
Mukhopadhyay P; Chowdhury S
J Indian Med Assoc; 2005 Nov; 103(11):603-5, 608. PubMed ID: 16570765
[TBL] [Abstract][Full Text] [Related]
9. Impaired glucose tolerance and impaired fasting glucose.
Rao SS; Disraeli P; McGregor T
Am Fam Physician; 2004 Apr; 69(8):1961-8. PubMed ID: 15117017
[TBL] [Abstract][Full Text] [Related]
10. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
Swanson A; Watrin K; Wilder L
J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
[TBL] [Abstract][Full Text] [Related]
11. From hyperglycemia to the risk of cardiovascular disease.
Leiter LA
Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
[TBL] [Abstract][Full Text] [Related]
12. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).
Barr EL; Zimmet PZ; Welborn TA; Jolley D; Magliano DJ; Dunstan DW; Cameron AJ; Dwyer T; Taylor HR; Tonkin AM; Wong TY; McNeil J; Shaw JE
Circulation; 2007 Jul; 116(2):151-7. PubMed ID: 17576864
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetes in patients with severe obesity.
Scheen AJ
Biomed Pharmacother; 2000 Mar; 54(2):74-9. PubMed ID: 10759290
[TBL] [Abstract][Full Text] [Related]
14. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
15. Self-reported prediabetes and risk-reduction activities--United States, 2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(44):1203-5. PubMed ID: 18987616
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of type 2 diabetes--an overview].
Qvigstad E
Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3047-50. PubMed ID: 15586184
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
18. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
19. Detection of undiagnosed diabetes and prediabetic states in high-risk emergency department patients.
Charfen MA; Ipp E; Kaji AH; Saleh T; Qazi MF; Lewis RJ
Acad Emerg Med; 2009 May; 16(5):394-402. PubMed ID: 19302369
[TBL] [Abstract][Full Text] [Related]
20. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
